Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19859621 | 1.00 | HRH4 (0.35) | HRH4HRH3ALDH1A1MEN1GLA | |
| SCHEMBL24387886 | 0.78 | SCN10A (0.42) | HRH4HRH3ALDH1A1MEN1GLA | |
| SCHEMBL7939302 | 0.71 | TDP1 (0.33) | — | |
| SCHEMBL8543644 | 0.69 | TAAR1 (0.44) | ALDH1A1DPP4 | |
| SCHEMBL24387888 | 0.69 | GPR84 (0.41) | HRH3 | |
| SCHEMBL18682135 | 0.69 | HRH3 (0.72) | HRH4HRH3ALDH1A1MEN1GLA | |
| SCHEMBL17603635 | 0.65 | HRH4 (0.31) | HRH4HRH3ALDH1A1MEN1GLA | |
| SCHEMBL16829251 | 0.65 | HRH4 (0.31) | HRH4HRH3ALDH1A1MEN1GLA | |
| SCHEMBL347325 | 0.64 | — | — | |
| SCHEMBL2361621 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3497098-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2019-06-06 | — | — | US | disclosed |
| WO-2018031877-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, DNPEP, FOLH1 | HRH4 1747/4885HRH3 2210/4885ALDH1A1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.